Morning sickness affects 70-80% of all pregnant women. About 60% of them experience nausea and vomiting. Morning sickness can decrease pregnant women’s work efficiency, result in unnecessary healthcare expenses, and negatively impact the quality of life of both the mothers and the unborn children. Some women even choose to have an abortion due to the severity of the symptoms.
One of the worst drug disasters in history resulted from an attempt to cease morning sickness with medications. Thalidomide, sold under the name, Immunoprin, was an anti-morning sickness drug used in the 1950s. This resulted in about 10,000 cases of infants who were born with phocomelia (the underdevelopment or absent of limbs and vital organs); only 50% of the 10,000 infants survived. While many modern medications are used today with low risk factors, they often contain debilitating side-effects.
EmeTerm™ is a drug free, none-invasive, and precise neuronal electrical stimulation technology that prevents and relieves morning sickness. By releasing a particular low-frequency electrical pulse from the user’s wrist, EmeTerm™ adjusts the vagus nerve signals traveling to and from the stomach. This prevents or postpones the brain from transmitting nausea signals to the stomach. This then slows down the nausea-inducing irregular gastric contraction, and reduces the nauseous sensation for the users.
Safety is the number one priority of EmeTerm™. All the materials of the device meet medical standards. EmeTerm™ uses medical silicone, instead of natural rubber, making the device hypoallergenic. Inert metal is used at electrode to avoid skin irritation. The patented electrodes are parallel with tendon, which enhances the electric conduction, and removes the need for conduction gel with potentially allergenic chemical compounds. EmeTerm™ has been recognized for its intuitive and user-friendly design and received the iF Design Award 2017.